Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
holding | IQMD | Class A Common Stock | 200K | Apr 17, 2023 | See Footnotes | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
holding | IQMD | Equity Swap | Apr 17, 2023 | Warrants | 1.07K | See Footnotes | F1, F2, F3 |
Id | Content |
---|---|
F1 | This statement is being filed by The Goldman Sachs Group, Inc. ("GS Group") and Goldman Sachs & Co. LLC ("Goldman Sachs" and together with GS Group, the "Reporting Persons"). Goldman Sachs is a subsidiary of GS Group. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein. Due to a reduction in the number of outstanding shares of Class A Common Stock as first publicly announced by Intelligent Medicine Acquisition Corp. (the "Issuer") on April 17, 2023, the Reporting Persons involuntarily became greater than 10% beneficial owners of the outstanding Class A Common Stock. |
F2 | The securities of the Issuer reported herein as indirectly purchased were beneficially owned directly by Goldman Sachs and indirectly by GS Group. |
F3 | Goldman Sachs is a party to an equity swap agreement which, upon the termination of the agreement on December 15, 2026 the counterparty will receive from Goldman Sachs any increase in the price of the Warrants above $0.00 per share, based on a notional amount of 1,067 warrants. |